Financial Lp Hrt Sells 22,139 Shares of Clearmind Medicine (NASDAQ:CMND) Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 22,139 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total value of $73,280.09. Following the sale, the insider directly owned 81,353 shares of the company’s stock, valued at $269,278.43. The trade was a 21.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, June 15th, Financial Lp Hrt sold 3,183 shares of Clearmind Medicine stock. The shares were sold at an average price of $3.32, for a total value of $10,567.56.
• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total value of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The stock was sold at an average price of $0.12, for a total value of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt acquired 2,159,052 shares of Clearmind Medicine stock. The stock was purchased at an average price of $0.15 per share, for a total transaction of $323,857.80.

Clearmind Medicine Stock Performance

CMND traded down $0.07 during trading on Thursday, hitting $3.07. The stock had a trading volume of 1,278,207 shares, compared to its average volume of 1,141,953. The firm has a market capitalization of $3.13 million, a P/E ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a twelve month low of $2.10 and a twelve month high of $524.00. The company’s 50-day moving average price is $5.75 and its 200 day moving average price is $15.22.

Clearmind Medicine (NASDAQ:CMND) last released its earnings results on Monday, June 15th. The company reported ($6.78) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a research note on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.